Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

Zacks09-27

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well. Here's a recap of the week’s most important stories: Biogen, UCB ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470876345?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c","is_english":true,"pubTime":"2024-09-27 00:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2470876345","market":"us","top_or_hot":-1,"title":"Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More","media":"Zacks","content":"<div>\n<p>The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well.\nHere's a recap of the week’s most important stories:\nBiogen, UCB ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-bhvn-wve-160600751.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 00:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-stock-roundup-bhvn-wve-160600751.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well.\nHere's a recap of the week’s most important stories:\nBiogen, UCB ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-bhvn-wve-160600751.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-bhvn-wve-160600751.html","article_id":"2470876345","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1H9NqoSNLfLtMd2fyMlfBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470876345","pubTimestamp":1727366760,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well.Here's a recap of the week’s most important stories:. Biogen BIIB and partner UCB announced that the phase III PHOENYCS GO study, which evaluated the investigational drug candidate, dapirolizumab pegol, for the treatment of moderate-to-severe systemic lupus erythematosus , met the primary endpoint by demonstrating clinical improvement in moderate-to-severe SLE.The double-blind, placebo-controlled phase III PHOENYCS GO study evaluated dapirolizumab pegol as an add-on therapy to standard-of-care  versus placebo with SOC for treating SLE. Data from the study showed that dapirolizumab pegol, in combination with SOC, led to greater improvement in moderate-to-severe disease activity after 48 weeks compared with placebo in addition to SOC.Biohaven Ltd. BHVN announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline can","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4077":"互动媒体与服务","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","ZVRA":"Zevra Therapeutics","VNDA":"万达生物制药","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4530":"医药外包概念","CRL":"查尔斯河","BK4213":"石油与天然气的勘探与生产","BK4532":"文艺复兴科技持仓","WVE":"Wave Life Sciences Pte. Ltd","SCA":"Stellus Capital Investment Corporation","SOC":"Sable Offshore Corp.","SLE":"Super League Gaming Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4139":"生物科技","BK4588":"碎股","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BIIB":"渤健公司"},"translate_title":"生物技术股票综述：BHVN、WVE、ZVRA股票因更新、BIIB和UCBs研究数据等而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"ZVRA":1,"WVE":1,"VNDA":1,"SOC":1,"SLE":1,"SCA":1,"CRL":1,"BHVN":1},"content_text":"The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight as well.\nHere's a recap of the week’s most important stories:\nBiogen, UCB Lupus Study Data\nBiogen BIIB and partner UCB announced that the phase III PHOENYCS GO study, which evaluated the investigational drug candidate, dapirolizumab pegol, for the treatment of moderate-to-severe systemic lupus erythematosus (SLE), met the primary endpoint by demonstrating clinical improvement in moderate-to-severe SLE.\nThe double-blind, placebo-controlled phase III PHOENYCS GO study evaluated dapirolizumab pegol as an add-on therapy to standard-of-care (SOC) versus placebo with SOC for treating SLE. Data from the study showed that dapirolizumab pegol, in combination with SOC, led to greater improvement in moderate-to-severe disease activity after 48 weeks compared with placebo in addition to SOC.\nThe study also demonstrated clinical improvements in key secondary endpoints measuring disease activity and flares. The safety profile of dapirolizumab pegol was similar to that seen in the previous studies.\nFollowing the PHOENYCS GO study's success, BIIB and UCB plan to initiate a second phase III study, PHOENYCS FLY, on dapirolizumab pegol in 2024.\nFDA Rejects VNDA’s NDA\nShares of Vanda Pharmaceuticals Inc. VNDA were down after the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant, for the treatment of symptoms in gastroparesis.\nThe NDA included evidence of the candidate’s efficacy from two placebo-controlled studies. However, per the CRL, the FDA called for Vanda to conduct additional studies on tradipitant with a design that was inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding of the disease.\nAlso, per management, the FDA delayed its decision by more than 185 days and failed to meet the requirements specified by the Food Drug and Cosmetic Act (“FDCA”). Notably, the FDCA requires the FDA to review an NDA and provide either an approval or a possible hearing within 180 days of the filing. The FDA failed to do either. VNDA also stated that it had repeatedly asked the FDA to hold an advisory committee meeting to discuss the NDA for tradipitant that the regulatory body declined.\nDespite the FDA declining to approve tradipitant for treating symptoms in gastroparesis, the company will continue to pursue the marketing approval for tradipitant in the given indication.\nBHVN Stock Up on Study Data\nBiohaven Ltd. BHVN announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease. The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) following three years of treatment.\nAlso, treatment with troriluzole led to statistically significant improvements in the f-SARA at years one and two.\nBased on the positive data from the BHV4157-206-RWE study, along with previous safety and efficacy data, BHVN plans to submit a ND) for troriluzole in SCA with the FDA in the fourth quarter of 2024. Biohaven plans to launch troriluzole in the United States in 2025 upon a potential approval.\nWVE Surges on Study Data\nWave Life Sciences WVE announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.\nPer the interim data readout from the phase II FORWARD-53 study, treatment with WVE-N531 for 24 weeks resulted in a mean muscle content-adjusted dystrophin expression of 9% and unadjusted dystrophin of 5.5%. Treatment with WVE-N531 for 24 weeks also resulted in myofiber regeneration and improvements in muscle health.\nThe interim data readout also showed significant decreases in creatine kinase and aspartate aminotransferase levels from baseline, signifying meaningful improvement in muscle health.\nWVE expects to share 48-week data from the complete FORWARD-53 study of WVE-N531 for DMD in the first quarter of 2025 and receive feedback from regulators on a pathway to accelerated approval.\nShares of WVE skyrocketed following the data announcement.\nZVRA Stock Rises on Drug Approval\nZevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC). The drug was approved under the brand name Miplyffa.\nThe FDA approved Miplyffa for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older. In addition, Zevra announced that it has received a rare pediatric disease priority review voucher in conjunction with the approval.\nThe approval of Miplyffa for the treatment of NPC is based on the totality of the data in the NDA, which included additional evidence supporting trial endpoints, FDA-preferred analyses and additional confirmatory evidence, both clinical and nonclinical.\nZevra stock skyrocketed to a new 52-week high following the announcement.\nPerformance\nThe Nasdaq Biotechnology Index has lost 3.46% in the past five trading sessions and MRNA’s shares have lost 8.90%. In the past six months, shares of AMGN have rallied 11.41%. (See the last biotech stock roundup here: Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates)\nImage Source: Zacks Investment Research\nWhat's Next in Biotech?\nStay tuned for more pipeline updates. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBiogen Inc. (BIIB) : Free Stock Analysis Report\nVanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report\nWAVE Life Sciences Ltd. (WVE) : Free Stock Analysis Report\nBiohaven Ltd. (BHVN) : Free Stock Analysis Report\nZevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470876345"}